Affiris Ag

Intercell Ag

Boehringer Ingelheim International Gmbh

Genentech, Inc.

The University of North Carolina at Chapel Hill

Valneva Austria Gmbh

Affiris Forschungs-und Entwicklungs Gmbh

Boehringer Ingelheim Gmbh

Genetech, Inc.

Advantage Therapeutics, Inc.

Accanis Biotech F&e Gmbh & Co Kg

Walter G Schmidt

Frank Mattner

Karen Lingnau

Max L Birnstiel

Achim Schneeberger

David T Curiel

Matthew Cotten

Ernst Wagner

Michael Buschle

Markus Mandler

Berndt Oberhauser

Kurt Zatloukal

Christian Plank

Alena Egyed

Arne Von Bonin

Andreas Mairhofer

Carola Schellack

Carola Wenander

Guenther Staffler

Wolfgang Zauner

Sylvia Brunner

Peter Steinlein

Andrea Dolischka

Tamàs Schweighoffer

Barbara Wittmann

Petra Luehrs

Petra Lührs

Günther Staffler

Martina Lutterova

Franck Mattner

Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.

Treatment of Alzheimer's Disease (AD) with an aluminum salt

The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with &#x3b2;-amyloid deposition, preferably AD.

Treatment and prevention of alzheimer's disease (AD)

Treatment of alzheimer'S disease (AD) with an aluminum salt

The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.

Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide

Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A&#x3b2;-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: &#x2014;contacting the sample with A&#x3b2;-aggregates or with particles having A&#x3b2;-aggregate like surfaces and allowing the A&#x3b2;-specific antibodies to bind to the A&#x3b2;-aggregates, and &#x2014;detecting the A&#x3b2;-specific antibodies bound to the A&#x3b2;-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A&#x3b2;-specific antibodies detected is compared with the amount in a sample of known AD status.

Method for diagnosing alzheimer's disease (AD)

Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2&#x2032; deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5&#x2032; or 3&#x2032; ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.

Methods and compositions involving immunostimulatory oligodeoxynucleotides

Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence 

Vaccine

The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes

Treatment of atherosclerosis with cholesterol ester transport protein mimotopes

Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I) 

The invention relates to the use of a compound comprising the following amino acid sequence XXXXXXX, wherein X1 is an amino acid, except of C, Xis an amino acid, except of C, Xis an amino acid, except of C, Xis an amino acid, except of C, Xis an amino acid, except of C, Xis not present or any amino acid, Xis not present or any amino acid, and wherein XXXXXXis not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal A&#x3b2;42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal A&#x3b2;42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.

Method for preventing and treating Alzheimer's disease

The invention relates to a method for treating Alzheimer's disease by inducing sequestration of amyloid &#x3b2; into a plasma with a A&#x3b2;-mimotope peptide, and treatment with an apheresis device such that a fixed carrier can come into contact with the blood or plasma flow and includes a receptor that binds to an amyloid-&#x3b2; precursor-protein (APP), the APP being removed from the blood with the apheresis device.

Combination therapy for the treatment of Alzheimer's disease

The invention relates to an apheresis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.

Methods of treating Alzheimer's Disease with an apheresis device

Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any X is O or S, any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2&#x2032; deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5&#x2032; or 3&#x2032; ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.

Immunostimulatory oligodeoxynucleic molecules

The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides&#x2014;start with a methionine amino acid residue,&#x2014;comprise an antigenic determinant and&#x2014;comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.

Antigens encoded by alternative reading frames from pathogenic viruses

Growing community of inventors

Vienna, Austria

Walter G Schmidt